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Cationic gold(I) heteroleptic complexes bearing a
pyrazole-derived N-heterocyclic carbene: syntheses,
characterizations, and cytotoxic activities†
Haresh Sivaram,a Jackie Tanb and Han Vinh Huynh*a
A series of cationic gold(I) heteroleptic complexes bearing the pyrazole-derived N-heterocyclic carbene
(NHC) FPyr (1,2,3,4,6,7,8,9-octahydropyridazino[1,2-a]indazolin-11-ylidene), and either a 1,3-disubstituted
benzimidazole-derived NHC of the type RR’-bimy (3: R = R’ = CHPh2; 4: R = CHPh2, R’ =
iPr; 5: R = R’ =
CH2Ph; 6: R = R’ =
iBu; 7: R = R’ = n-Pr; 8: R = R’ = Et; 9: R = R’ = 2-propenyl) or a non-NHC co-ligand L (10:
L = PPh3; 11: L = P(OPh)3; 12: L = DMAP) (DMAP = 4-dimethylaminopyridine) have been synthesized from
[AuCl(FPyr)] (1). Complexes 3–12 have been characterized using multinuclei NMR spectroscopies, ESI
mass spectrometry, and elemental analysis. X-ray diﬀraction analyses have been performed on complexes
5, 6, and 9–11. To the best of our knowledge, 11 represents the ﬁrst gold–NHC complex to bear the
P(OPh)3 ligand. The cytotoxic activities of complexes 3–12 have been studied in vitro with the NCI-H1666
non-small cell lung cancer cell line.
Introduction
Interest in the cytotoxic activities of gold complexes has grown
tremendously over the years.1,2 In particular, gold complexes
bearing N-heterocyclic carbenes (NHCs) have been gaining
much attention,3 given the ease with which NHC precursors
can be tuned, both electronically and sterically, by varying the
N-substituents.4 This in turn allows for synthetic control of the
hydro- and lipophilic properties of the resultant complexes;
properties that have been shown to be important factors in the
development of gold-based anti-cancer agents.2,3 However,
only gold mono- and homo-bis(carbene) complexes bearing
imidazolin-2-ylidenes have been extensively studied,2,3 whereas
complexes bearing other types of NHCs, as well as heteroleptic
complexes, have been scarcely considered.5
Therefore, as our maiden contribution to this field of
research, we had recently published the cytotoxic activities of a
range of gold(I) and gold(III) mono-, homo-bis- and hetero-bis-
(carbene) complexes bearing benzimidazole- and/or pyrazole-
derived NHC ligands on the NCI-H1666 non-small cell lung
cancer cell line.6 The preliminary study revealed that the
cationic bis(carbene) complexes are far more active as cytotoxic
agents when compared with the neutral monocarbene com-
plexes. The gold(I) hetero-bis(carbene) complex 2 (Fig. 1), in
particular, shows superior performance with an IC50 value of
0.241 μM. Based on these findings, it was proposed that a
heteroleptic system in which a strongly donating ligand is situated
trans to a relatively weaker donating ligand was necessary for
the labilization of the latter. This would create a vacant coordi-
nation site that may be essential for the cytotoxic activity of
the complex. For example, donor atoms on target proteins,
such as thioredoxin reductase,2,5,7 could bind to the complex
fragment when a free coordination site is made available.
Spurred by the findings of our initial study, we have
extended the investigation to consider a range of other cationic
gold(I) heteroleptic complexes bearing the strongly donating
pyrazole-derived FPyr (1,2,3,4,6,7,8,9-octahydropyridazino[1,2-a]-
indazolin-11-ylidene) ligand, and either a 1,3-disubstituted
benzimidazole-derived NHC, or a non-NHC co-ligand. Ben-
zimidazolin-2-ylidenes bearing a variety of N-substituents have
Fig. 1 Gold(I) hetero-bis(carbene) complex [Au(FPyr)(iPr2-bimy)]PF6 (2).
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been considered, in an eﬀort to study the eﬀect on the cytotoxi-
city of the resultant complexes. For the purpose of compari-
son with our previous work, the cytotoxic activities of the
complexes were studied in vitro with the NCI-H1666 non-small
cell lung cancer cell line. We herein report on the syntheses,




The gold(I) chlorido-monocarbene complex [AuCl(FPyr)] (1)
was synthesized according to the previously reported pro-
cedure.6 Reaction of 1 with the appropriate 1,3-disubstituted
benzimidazolium salts in the presence of K2CO3 aﬀorded the
gold(I) hetero-bis(carbene) complexes 3–9 in very good yields
ranging from 72 to 82% (Scheme 1). The heteroleptic com-
plexes 10–12, which bear non-NHC co-ligands, were syn-
thesized via straightforward ligand exchange reactions.
Complex 1 was reacted with the appropriate pro-ligand in the
presence of a large excess of KPF6 in acetone, and the products
were obtained in very good yields of 77 to 94% (Scheme 1). All
ten complexes were obtained as white powders, and are
soluble in most polar organic solvents. It should be noted that
11 represents the first gold–NHC complex to bear a phosphite
co-ligand.
Complexes 3–12 were characterized using MS (ESI) and
multinuclei NMR spectroscopies. The MS (ESI) spectra of the
complexes were particularly useful in confirming the for-
mation of the compounds, given that the base peak observed
in all cases corresponds to the [M − PF6]+ fragment. 1H NMR
spectroscopy corroborated the successful formation of the
complexes, whereby signals from both ligands are observed in
the respective spectra. For complexes 3–9, the 13C NMR spectra
correspondingly featured two downfield signals as a result of
the presence of two carbene carbon atoms in the molecules.
These two signals were assigned to their respective carbene
carbon atoms by using the previously reported complex 2 as a
reference.6 The chemical shift(s) of the carbene carbon atom(s)
in complexes 3–12 are presented in Table 1.
Considering the chemical shift of the FPyr carbene carbon,
it is overt that as compared to the gold(I) chlorido monocar-
bene complex 1 (cf. 167.8 ppm),6 the FPyr carbene carbon in
complexes 3–11, resonate at a much more downfield region,
ranging from 178.8–182.4 ppm. This is due to the replacement
of the chlorido co-ligand in 1 with a stronger donating ligand
situated trans to the FPyr ligand in the mentioned complexes,
leading to the observed downfield shift of the signal.6,8 On the
other hand, complex 12, with its DMAP co-ligand, shows a
more upfield FPyr carbene carbon resonance as compared to
1, which is the result of DMAP being a weaker donating ligand
as compared to the chlorido ligand.
The changes in the chemical shift of the FPyr carbene
carbon also reveal other interesting, albeit unexpected, find-
ings. For example, when focusing on the relevant data for
hetero-bis(carbene) complexes 3–9, it is noteworthy that no
real correlation can be drawn between the chemical shift of
the FPyr carbene carbon and the N-substituents of the RR′-
bimy ligands, where the latter would inadvertently influence
the overall donating ability of said RR′-bimy ligands. This is
Scheme 1 Syntheses of cationic gold(I) hetero-bis(carbene) complexes of the type [Au(FPyr)(RR’-bimy)]PF6 (3–9), and heteroleptic complexes of the type [Au(FPyr)-
(L)]PF6 (10–12).
Table 1 Chemical shift(s) of the carbene carbon atom(s) in complexes of the
type [Au(FPyr)(L)]PF6 (3–12)
a
Complex L FPyr RR′-bimy
3 (CHPh2)2-bimy 178.8 197.8
4 (iPr2)(CHPh2)-bimy 179.2 195.1
5 (CH2Ph)2-bimy 179.9 195.7
6 iBu2-bimy 180.2 194.8
7 n-Pr2-bimy 180.0 194.8
8 Et2-bimy 180.7 194.1
9 (2-Propenyl)2-bimy 179.9 196.0
10 PPh3 182.4 —
11 P(OPh)3 179.6
b —
12 DMAP 161.0 —
a All 13C NMR spectra were measured in CDCl3, except for complexes 7,
9 and 12, which were measured in CD3CN due to poor solubility in
chloroform. bDoublet, 2J(C,P) = 178 Hz.
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unlike the 13C NMR spectroscopic methodology for determin-
ing ligand donor strengths that has been reported by our
group, wherein even small changes to the N-substituents of
various NHCs are shown to aﬀect the donating ability of the
ligands, and can be detected by the iPr2-bimy probe in com-
plexes of the type [PdBr2(
iPr2-bimy)(NHC)].
4a Therefore, the
data presented in this work seems to suggest that the Au(I)
system is less sensitive than the Pd(II) system when it comes to
detecting small changes in donor strength. Furthermore, while
the Pd(II) system is able to confirm the stronger donating
ability of NHCs as compared to phosphines, the Au(I) system
studied in this work suggests the reverse, with the FPyr
carbene carbon in [Au(FPyr)(PPh3)]PF6 (10) resonating at
182.4 ppm, which is significantly more downfield as compared
to the hetero-bis(carbene) complexes 3–9. This may be due to
some unique interactions that the phosphorus donor in PPh3
has with the electron-rich gold(I) metal center, and warrants
further investigation.
Single crystals suitable for X-ray diﬀraction analysis were
obtained for complexes 5, 6, and 9–11 via vapour diﬀusion of
diethyl ether into solutions of the compounds in either CHCl3
or CH2Cl2. The determined molecular structures were as
expected, with all complexes adopting a linear geometry about
the gold(I) metal center (Fig. 2). Complex 5 crystallised as the
chloroform solvate, while all other complexes crystallised
unsolvated. It is interesting to note that unlike 5, where both
the benzyl N-substituents are arranged in an anti arrangement
across the benzimidazole plane, the N-substituents in 6 and 9
are arranged in a syn arrangement, which is a result of achiev-
ing optimum packing in the unit cell. Two of the carbon
atoms (C29 and C30) in the alicyclic ring of the FPyr ligand in
5 were also disordered into two positions, with an occupancy
ratio of 50 : 50. The molecular structure of complex 11 is par-
ticularly interesting, in that two of the phenyl rings of the
P(OPh)3 ligand are pointed towards the gold metal center. The
remaining one is pointed away as a result of the close proxi-
mity of a PF6
− anion. The potential steric shielding of the
metal center accorded by the phenyl rings is unique to this
ligand, and could prove beneficial for the overall stability of
the complex. Furthermore, it is worth noting that none of the
complexes showed evidence for intermolecular aurophilic
interactions in the solid state.9
Cytotoxicity study
The cytotoxic activities of complexes 3–12 were investigated
through a cell proliferation assay conducted on the NCI-H1666
non-small cell lung cancer cell line, and IC50 values were
obtained from best-fit dose response curves (see ESI†). The
performance of each complex in comparison to the previously
reported complex 2, as well as cisplatin, is tabulated in
Table 2.
Considering the hetero-bis(carbene) complexes 3–9, it is
noted that they do not perform as well as the previously
reported complex 2, although 3 does come close with an IC50
value of 0.346 μM. Also, there seems to be no con-
sistent relationship between the nature and length of the
Fig. 2 Molecular structures of complexes 5·CHCl3, 6, and 9–11 showing 50% probability ellipsoids; hydrogen atoms, PF6
− anions, and solvent molecules (if any) are
omitted for clarity. Selected bond lengths [Å] and angles [°]: 5·CHCl3: Au1–C1 2.017(5), Au1–C22 2.015(5); C1–Au1–C22 177.7(2); 6: Au1–C1 2.027(5), Au1–C16
2.013(5); C1–Au1–C16 174.85(19); 9: Au1–C1 2.020(3), Au1–C14 2.018(3); C1–Au1–C14 176.81(12); 10: Au1–C1 2.035(6), Au1–P1 2.2843(17); C1–Au1–P1 175.43(17);
11: Au1–C1 2.030(6), Au1–P1 2.2426(18); C1–Au1–P1 177.17(18).
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N-substituents on the benzimidazole-derived NHC and the
activity of the complexes. However, it is worth noting that com-
plexes 2 and 3, which both bear symmetrically substituted benz-
imidazole-derived NHCs, with both N-substituents being 2°
carbon atoms, show superior performance as compared to
complexes that bear benzimidazole-derived NHCs with either
asymmetric N-substituents (i.e. complex 4), or 1° carbon atom
N-substituents (i.e. complexes 5–9). This does suggest some
form of structure–activity relationship, although further
studies would be necessary to better understand the relative
performance. Among the hetero-bis(carbene) complexes, 9 is
an exception, and this may be attributed to the presence of
reactive allyl moieties that make the complex more susceptible
to addition and redox reactions, possibly degrading and/or
deactivating the complex.
While the presence of a labile ligand seems necessary for
the superior activity of these gold(I) complexes, it is apparently
also important that the ligand trans to the FPyr ligand is not
too weakly bound to the metal center. Evidence for this is
found when considering complexes 10–12. As we progress
from the stronger donating PPh3 to the much weaker donating
DMAP, there is an increase in the IC50 values. Since the mode
of action of other cationic gold–NHC complexes has been
reported to involve permeation into the mitochondria,1,2,7 it is
possible that in the case of complex 12, for example, the
DMAP ligand detaches from the complex cation prematurely
and prior to entering the mitochondria. This may potentially
deactivate the compound even before it reaches its target site.
Therefore, a fine balancing of these various properties seems
necessary for the development of an optimum complex.
Conclusion
We have reported on the syntheses and characterizations of a
series of cationic gold(I) heteroleptic complexes bearing the
pyrazole-derived FPyr ligand, and either a benzimidazole-
derived NHC of the type RR′-bimy (3–9), or a non-NHC co-
ligand L (10–12). Complexes 3–9 were synthesized using [AuCl-
(FPyr)] (1) and the appropriate disubstituted benzimidazolium
salt in the presence of K2CO3. 10–12, on the other hand, were
synthesized using 1 and the necessary pro-ligand in the pres-
ence of an excess of KPF6. The cytotoxic activities of all ten
complexes were studied with the NCI-H1666 non-small cell
lung cancer cell line, and their performances were compared
with the previously reported activity of the gold(I) hetero-bis
(carbene) complex [Au(FPyr)(iPr2-bimy)]PF6 (2), and cisplatin.
While the complexes reported in this work are not as cytotoxic
as 2, some do show comparable performance, and most com-
plexes perform better than cisplatin. Our lab is currently in the
midst of further investigations of some of the complexes,
focussing primarily on their physiochemical and pharmaco-
kinetic properties, as well as their in vitro toxicities to healthy
cell lines. We look forward to reporting our findings from
these studies in the near future.
Experimental
General considerations
All operations were performed without taking precautions to
exclude air and moisture, and all solvents and chemicals were
used as received. 1H, 13C, 19F and 31P NMR spectra were
recorded on a Bruker ACF 300 spectrometer or a Bruker AMX
500 spectrometer. The chemical shifts (δ) were internally refer-
enced to the residual solvent signals relative to tetramethylsi-
lane (1H and 13C), or externally to CF3CO2H (
19F) and 85%
H3PO4 (
31P). ESI mass spectra were measured using a Finnigan
LCQ spectrometer. Elemental analyses were performed on an
Elementar Vario Micro Cube elemental analyser at the Depart-
ment of Chemistry, National University of Singapore. Complex 1
was synthesized as previously reported.6 The azolium salts 1,3-
dibenzhydrylbenzimidazolium bromide,10 1,3-dibenzylbenzimi-
dazolium bromide,10 1,3-diisobutylbenzimidazolium bromide,10
1,3-dipropylbenzimidazolium bromide,11 1,3-diethylbenzimida-
zolium bromide,12 and 1,3-di(2-propenyl)benzimidazolium
bromide13 were synthesized according to literature procedures,
albeit with slight modifications. 1-Benzhydryl-3-isopropylbenz-
imidazolium bromide was synthesized from 1-benzhydrylbenz-
imidazole, and the procedures for the syntheses of both are
reported in this section. All azolium salts were converted to
their hexafluorophosphate analogues via salt metathesis
reaction with KPF6 in acetone, stirred overnight at ambient
temperature.
1-Benzhydrylbenzimidazole. Benzimidazole (1.18 g,
10 mmol) was suspended in CH3CN (20 mL). NaOH (1.60 mL,
10 mmol, 6.25 M) was added to the suspension, and the reac-
tion mixture was stirred for 30 min before a solution of benz-
hydryl bromide (2.47 g, 10 mmol) dissolved in CH3CN (10 mL)
was added. The reaction mixture was heated under reflux over-
night, following which it was filtered through Celite. The fil-
trate was dried over anhydrous Na2SO4, filtered, and all
volatiles were removed under vacuum aﬀording a beige oil.
The crude product was purified by flash column chromato-
graphy (silica gel, ether) (1.45 g, 5.1 mmol, 51%). 1H NMR
(300 MHz, CDCl3): δ 7.84 (d, 1 H, Ar–H), 7.63 (s, 1 H, NCHN),
7.38–7.14 (m, 13 H, Ar–H), 6.76 (s, 1 H, NCHPh2).
13C{1H}
Table 2 Cytotoxicity of complexes of the type [Au(FPyr)(L)]PF6 (2–12) and
cisplatin expressed as IC50 values
Complex L IC50 (μM)
26 iPr2-bimy 0.241 ± 0.01
3 (CHPh2)2-bimy 0.346 ± 0.03
4 (iPr)(CHPh2)-bimy 2.01 ± 0.20
5 (CH2Ph)2-bimy 0.720 ± 0.18
6 iBu2-bimy 0.964 ± 0.06
7 n-Pr2-bimy 1.91 ± 0.40
8 Et2-bimy 0.747 ± 0.08
9 (2-Propenyl)2-bimy 5.10 ± 0.10
10 PPh3 2.15 ± 0.22
11 P(OPh)3 3.04 ± 0.27
12 DMAP >10
Cisplatin6 — 2.51 ± 0.11
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NMR (75.5 MHz, CDCl3): δ 144.0 (Ar–C), 142.5 (NCHN), 138.0,
134.0, 129.0, 128.5, 128.2, 123.0, 122.4, 120.3, 110.7 (Ar–C),
63.6 (NCHPh2).
1-Benzhydryl-3-isopropylbenzimidazolium bromide. 1-Benz-
hydrylbenzimidazole (1.42 g, 5.0 mmol) was suspended in
CH3CN (2 mL). Isopropyl bromide (0.5 mL, 5.3 mmol) was
added to the suspension, and the reaction mixture was
refluxed for 24 h. After cooling to ambient temperature, all
volatiles were removed under vacuum. The crude product was
washed several times with ethyl acetate and dried under
vacuum to yield a white solid (1.58 g, 3.9 mmol, 78%). 1H
NMR (300 MHz, CDCl3): δ 11.32 (s, 1 H, NCHN), 7.99 (s, 1 H,
NCHPh2), 7.80–7.17 (m, 14 H, Ar–H), 5.18–5.04 (m, 1 H, NCH
(CH3)2), 1.83 (d, 6 H, CH3).
13C{1H} NMR (75.5 MHz, CDCl3): δ
147.9 (NCHN), 141.9, 135.6, 131.3, 131.0, 129.2, 129.1, 128.6,
126.82, 126.76, 115.8, 113.7 (Ar–C), 66.5 (NCHPh2), 52.2 (NCH
(CH3)2), 22.2 (CH3). MS (ESI): m/z = 327 [M − Br]+.
General procedure for the synthesis of gold(I) hetero-bis-
(carbene) complexes 3–9
Complex 1 (1 equiv.) and the appropriate azolium hexafluoro-
phosphate salt (1 equiv.) were dissolved in acetone. K2CO3 (1.3
equiv.) was added to the solution, and the resulting mixture
was stirred for 24 h at ambient temperature. The solvent of the
reaction mixture was then removed under vacuum. The residue
was suspended in CH2Cl2 and filtered over Celite. The solvent
of the filtrate was removed under vacuum, and the resulting
residue was washed thrice with ethyl acetate or diethyl ether.
The crude product was purified by crystallization via vapour
diﬀusion of diethyl ether into a solution of the compound in
CHCl3 or CH2Cl2. All complexes were obtained as colourless
crystals.
[Au(FPyr)((CHPh2)2-bimy)]PF6 (3). Yield: 82%.
1H NMR
(500 MHz, CDCl3): δ 7.66 (s, 2 H, NCH), 7.40–7.38 (m, 12 H,
Ar–H), 7.28–7.27 (m, 8 H, Ar–H), 7.17 (dd, 2 H, Ar–H), 7.05 (dd,
2 H, Ar–H), 4.02 (t, 2 H, 3J(H,H) = 5.70 Hz, NCH2), 3.88 (t, 2 H,
3J(H,H) = 5.70 Hz, NCH2), 2.56 (t, 2 H,
3J(H,H) = 6.30 Hz, CH2),
2.34 (t, 2 H, 3J(H,H) = 5.70 Hz, CH2), 2.12 (m, 2 H, CH2), 2.01
(m, 2 H, CH2), 1.82 (m, 2 H, CH2), 1.70 (m, 2 H, CH2).
13C{1H}
NMR (125.8 MHz, CDCl3): δ 197.8 (Ccarbene ((CHPh2)2-bimy)),
178.8 (Ccarbene (FPyr)), 144.4, 137.9, 134.5, 129.7, 129.5, 129.0,
126.3, 125.3, 114.6 (Ar–C), 68.8 (NCH), 51.5, 46.5 (NCH2), 23.3,
22.9, 22.5, 21.9, 21.2, 21.0 (CH2).
31P{1H} NMR (202.4 MHz,
CDCl3): δ −143.8 (m, PF6). 19F{1H} NMR (282.4 MHz, CDCl3): δ
2.30 (d, PF6). Anal. Calc. for C44H42N4AuPF6: C, 54.55; H, 4.37;
N, 5.78. Found: C, 54.54; H, 4.26; N, 5.61%. MS (ESI): m/z =
823 [M − PF6]+.
[Au(FPyr)((iPr)(CHPh2)-bimy)]PF6 (4). Yield: 76%.
1H NMR
(500 MHz, CDCl3): δ 7.73 (d, 1 H, Ar–H), 7.68 (s, 1 H, NCHPh2),
7.42–7.28 (m, 11 H, Ar–H), 7.22 (t, 1 H, Ar–H), 7.03 (d, 1 H, Ar–
H), 5.40 (m, 1 H, 3J(H,H) = 6.30 Hz, NCH(CH3)2), 4.20 (br t,
2 H, NCH2), 4.09 (br t, 2 H, NCH2), 2.62 (br t, 2 H, CH2), 2.52
(br t, 2 H, CH2), 2.16 (br m, 4 H, CH2), 1.88 (d, 6 H,
3J(H,H) = 6.30
Hz, CH3), 1.77 (br m, 2 H, CH2), 1.31 (br m, 2 H, CH2).
13C{1H}
NMR (125.8 MHz, CDCl3): δ 195.1 (Ccarbene ((
iPr)(CHPh2)-
bimy)), 179.2 (Ccarbene (FPyr)), 144.4, 138.0, 134.2, 133.4, 129.7,
129.6, 129.3, 129.0, 126.4, 125.13, 125.07, 114.6, 113.5 (Ar–C),
68.8 (NCHPh2), 54.0 (NCH(CH3)2), 51.7, 46.6 (NCH2), 23.31
(CH2), 23.29 (CH3), 23.0, 22.5, 21.9, 21.2, 21.0 (CH2).
31P{1H}
NMR (202.4 MHz, CDCl3): δ −143.8 (m, PF6). 19F{1H} NMR
(282.4 MHz, CDCl3): δ 2.34 (d, PF6). Anal. Calc. for
C34H38N4AuPF6·0.3CH2Cl2·0.6Et2O: C, 48.20; H, 4.92; N, 6.13.
Found: C, 48.29; H, 4.71; N, 6.01%. MS (ESI): m/z = 699
[M − PF6]+.
[Au(FPyr)((CH2Ph)2-bimy)]PF6 (5). Yield: 80%.
1H NMR
(500 MHz, CDCl3): δ 7.44–7.31 (m, 14 H, Ar–H), 5.77 (s, 4 H,
NCH2Ph), 4.22 (t, 2 H,
3J(H,H) = 5.70 Hz, NCH2), 4.03 (t, 2 H,
3J(H,H) = 5.70 Hz, NCH2), 2.57 (t, 2 H,
3J(H,H) = 6.30 Hz, CH2),
2.50 (t, 2 H, 3J(H,H) = 6.30 Hz, CH2), 2.09 (m, 4 H, CH2), 1.83
(m, 2 H, CH2), 1.72 (m, 2 H, CH2).
13C{1H} NMR (125.8 MHz,
CDCl3): δ 195.7 (Ccarbene ((CH2Ph)2-bimy)), 179.9 (Ccarbene
(FPyr)), 144.4, 135.8, 134.2, 129.8, 129.2, 127.9, 126.7, 125.6,
112.8 (Ar–C), 52.9 (NCH2Ph), 51.7, 46.6 (NCH2), 23.3, 22.9,
22.5, 21.9, 21.3, 21.1 (CH2).
31P{1H} NMR (202.4 MHz, CDCl3):
δ −143.7 (m, PF6). 19F{1H} NMR (282.4 MHz, CDCl3): δ 2.59 (d,
PF6). Anal. Calc. for C32H34N4AuPF6: C, 47.07; H, 4.20; N, 6.86.
Found: C, 47.15; H, 4.25; N, 6.87%. MS (ESI): m/z = 671
[M − PF6]+.
[Au(FPyr)(iBu2-bimy)]PF6 (6). Yield: 74%.
1H NMR
(500 MHz, CDCl3): δ 7.52 (dd, 2 H, Ar–H), 7.44 (dd, 2 H, Ar–H),
4.40 (br t, 2 H, NCH2), 4.31 (d, 4 H,
3J(H,H) = 7.55 Hz, NCH2CH-
(CH3)2), 4.10 (br t, 2 H, NCH2), 2.62 (t, 2 H,
3J(H,H) = 6.30 Hz,
CH2), 2.59 (t, 2 H,
3J(H,H) = 6.30 Hz, CH2), 2.44 (m, 2 H,
NCH2CH(CH3)2), 2.19 (br t, 4 H, CH2), 1.87 (m, 2 H, CH2), 1.79
(m, 2 H, CH2), 1.03 (d, 12 H,
3J(H,H) = 6.30 Hz, CH3).
13C{1H}
NMR (125.8 MHz, CDCl3): δ 194.8 (Ccarbene (
iBu2-bimy)), 180.2
(Ccarbene (FPyr)), 144.5, 134.3, 126.6, 125.3, 112.5 (Ar–C), 56.4
(NCH2CH(CH3)2), 51.8, 46.6 (NCH2), 30.2 (NCH2CH(CH3)2),
23.4, 23.0, 22.5, 22.0, 21.3, 21.1 (CH2), 21.0 (CH3).
31P{1H}
NMR (202.4 MHz, CDCl3): δ −143.7 (m, PF6). 19F{1H} NMR
(282.4 MHz, CDCl3): δ 2.49 (d, PF6). Anal. Calc. for
C26H38N4AuPF6: C, 41.72; H, 5.12; N, 7.48. Found: C, 41.52; H,
5.10; N, 7.31%. MS (ESI): m/z = 603 [M − PF6]+.
[Au(FPyr)(n-Pr2-bimy)]PF6 (7). Yield: 79%.
1H NMR
(500 MHz, CD3CN): δ 7.67 (dd, 2 H, Ar–H), 7.47 (dd, 2 H, Ar–
H), 4.49 (t, 4 H, 3J(H,H) = 6.90 Hz, NCH2CH2CH3), 4.41 (br t,
2 H, NCH2), 4.04 (br t, 2 H, NCH2), 2.60 (m, 4 H, CH2), 2.10 (br t,
4 H, CH2), 1.99 (m, 4 H, CH2), 1.84 (m, 2 H, CH2), 1.76 (m,
2 H, CH2), 0.98 (t, 6 H,
3J(H,H) = 7.60 Hz, CH3).
13C{1H} NMR
(125.8 MHz, CD3CN): δ 194.8 (Ccarbene (n-Pr2-bimy)), 180.0 (Ccarbene
(FPyr)), 144.5, 134.2, 126.3, 125.1, 112.7 (Ar–C), 51.8 (NCH2),
50.6 (NCH2CH2CH3), 46.6 (NCH2), 24.2 (NCH2CH2CH3), 23.4,
22.8, 22.5, 21.7, 21.1, 20.8 (CH2), 11.5 (CH3).
31P{1H} NMR
(202.4 MHz, CD3CN): δ −143.2 (m, PF6). 19F{1H} NMR
(282.4 MHz, CD3CN): δ 3.43 (d, PF6). Anal. Calc. for
C24H34N4AuPF6: C, 40.01; H, 4.76; N, 7.78. Found: C, 40.04;
H, 4.40; N, 7.73%. MS (ESI): m/z = 575 [M − PF6]+.
[Au(FPyr)(Et2-bimy)]PF6 (8). Yield: 72%.
1H NMR (500 MHz,
CDCl3): δ 7.53 (dd, 2 H, Ar–H), 7.46 (dd, 2 H, Ar–H), 4.57 (m, 4
H, 3J(H,H) = 7.55 Hz, NCH2CH3), 4.47 (t, 2 H,
3J(H,H) = 5.65
Hz, NCH2), 4.09 (t, 2 H,
3J(H,H) = 6.30 Hz, NCH2), 2.62 (t, 4 H,
3J(H,H) = 6.30 Hz, CH2), 2.21 (m, 4 H, CH2), 1.89 (m, 2 H,
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CH2), 1.80 (m, 2 H, CH2), 1.60 (t, 6 H,
3J(H,H) = 7.60 Hz, CH3).
13C{1H} NMR (125.8 MHz, CDCl3): δ 194.1 (Ccarbene (Et2-bimy)),
180.7 (Ccarbene (FPyr)), 144.3, 133.7, 126.7, 125.3, 112.1 (Ar–C),
52.0, 46.7 (NCH2), 44.4 (NCH2CH3), 23.4, 23.0, 22.6, 22.0, 21.4,
21.2 (CH2), 16.6 (CH3).
31P{1H} NMR (202.4 MHz, CDCl3): δ
−143.8 (m, PF6). 19F{1H} NMR (282.4 MHz, CDCl3): δ 2.27 (d,
PF6). Anal. Calc. for C22H30N4AuPF6: C, 38.16; H, 4.37; N, 8.09.
Found: C, 38.38; H, 4.04; N, 8.09%. MS (ESI): m/z = 547
[M − PF6]+.
[Au(FPyr)((2-propenyl)2-bimy)]PF6 (9). Yield: 75%.
1H NMR
(500 MHz, CD3CN): δ 7.63 (dd, 2 H, Ar–H), 7.47 (dd, 2 H, Ar–
H), 6.14 (m, 2 H, NCH2CHvCH2), 5.28 (dm, 2 H,
3J(H,H) =
10.10 Hz, NCH2CHvCHHtrans), 5.16–5.19 (m, 6 H,
NCH2CHvCH2 and NCH2CHvCHHcis), 4.39 (t, 2 H,
3J(H,H) =
5.70 Hz, NCH2), 4.04 (t, 2 H,
3J(H,H) = 5.70 Hz, NCH2), 2.59
(m, 4 H, CH2), 2.09 (br t, 4 H, CH2), 1.84 (m, 2 H, CH2), 1.76
(m, 2 H, CH2).
13C{1H} NMR (125.8 MHz, CD3CN): δ 196.0 (Ccarbene
((2-propenyl)2-bimy)), 179.9 (Ccarbene (FPyr)), 144.7, 134.4,
133.7, 126.5, 125.6, 118.6, 113.1 (Ar–C and vinylic–C), 52.0
(NCH2), 51.5 (NCH2CHvCH2), 46.8 (NCH2), 23.6, 23.0, 22.7,
21.9, 21.3, 21.0 (CH2).
31P{1H} NMR (202.4 MHz, CD3CN): δ
−144.0 (m, PF6). 19F{1H} NMR (282.4 MHz, CD3CN): δ 3.46 (d,
PF6). Anal. Calc. for C24H30N4AuPF6: C, 40.23; H, 4.22; N, 7.82.
Found: C, 40.14; H, 4.36; N, 7.64%. MS (ESI): m/z = 571
[M − PF6]+.
General procedure for the synthesis of gold(I) heteroleptic
complexes 10–12
Complex 1 (1 equiv.) and the appropriate pro-ligand (1.2
equiv.) were dissolved in acetone. KPF6 (3 equiv.) dissolved in
acetone was added to the solution, and the resulting mixture
was stirred for 1 h at ambient temperature. The solvent of the
reaction mixture was then removed under vacuum. The residue
was suspended in CH2Cl2 and filtered over Celite. The solvent
of the filtrate was removed under vacuum, and the resulting
residue was washed thrice with diethyl ether. The crude
product was purified by crystallization via vapour diﬀusion of
diethyl ether into a solution of the compound in CH2Cl2. All
complexes were obtained as colourless crystals.
[Au(FPyr)(PPh3)]PF6 (10). Yield: 94%.
1H NMR (500 MHz,
CDCl3): δ 7.54–7.41 (m, 15 H, Ar–H), 4.41 (br t, 2 H, NCH2),
4.12 (br t, 2 H, NCH2), 2.60 (m, 4 H, CH2), 2.18 (br m, 4 H,
CH2), 1.86 (br m, 2 H, CH2), 1.77 (br m, 2 H, CH2).
13C{1H}
NMR (125.8 MHz, CDCl3): δ 182.4 (Ccarbene), 144.7 (Ar–C),
134.6, 132.5, 130.1, 130.0 (d, Ar–C), 126.4 (Ar–C), 52.0, 46.7
(NCH2), 23.2, 22.9, 22.5, 21.8, 21.2, 20.9 (CH2).
31P{1H} NMR
(202.4 MHz, CDCl3): δ 41.3 (PPh3), −143.8 (m, PF6). 19F{1H}
NMR (282.4 MHz, CDCl3): δ 2.32 (d, PF6). Anal. Calc. for
C29H31N2AuP2F6: C, 44.63; H, 4.00; N, 3.59. Found: C, 44.88; H,
3.89; N, 3.40%. MS (ESI): m/z = 635 [M − PF6]+.
[Au(FPyr)(P(OPh)3)]PF6 (11). Yield: 77%.
1H NMR (500 MHz,
CDCl3): δ 7.48–7.27 (m, 15 H, Ar–H), 4.02 (t, 2 H,
3J(H,H) = 5.70
Hz, NCH2), 3.79 (t, 2 H,
3J(H,H) = 6.30 Hz, NCH2), 2.52 (t, 2 H,
3J(H,H) = 6.30 Hz, CH2), 2.20 (t, 2 H,
3J(H,H) = 6.30 Hz, CH2),
2.10 (m, 2 H, CH2), 2.00 (m, 2 H, CH2), 1.78 (m, 2 H, CH2),
1.65 (m, 2 H, CH2).
13C{1H} NMR (125.8 MHz, CDCl3): δ 179.6
(d, 2J(C,P) = 178 Hz, Ccarbene), 150.1, 144.6, 131.3, 127.5, 126.6,
121.9 (d, Ar–C), 51.5, 46.6 (NCH2), 23.1, 22.4, 22.3, 21.4,
21.2, 20.7 (CH2).
31P{1H} NMR (202.4 MHz, CDCl3): δ 139.3
(P(OPh)3), −143.8 (m, PF6). 19F{1H} NMR (282.4 MHz, CDCl3): δ
2.35 (d, PF6). Anal. Calc. for C29H31N2O3AuP2F6: C, 42.04; H,
3.77; N, 3.38. Found: C, 42.30; H, 3.77; N, 3.62%. MS (ESI): m/z =
683 [M − PF6]+.
[Au(FPyr)(DMAP)]PF6 (12). Yield: 81%.
1H NMR (500 MHz,
CD3CN): δ 7.99 (d, 2 H, Ar–H), 6.68 (d, 2 H, Ar–H), 4.37 (br t,
2 H, NCH2), 4.00 (br t, 2 H, NCH2), 3.05 (s, 6 H, NCH3), 2.54
(m, 4 H, CH2), 2.06 (m, 4 H, CH2), 1.82 (br m, 2 H, CH2), 1.73
(br m, 2 H, CH2).
13C{1H} NMR (125.8 MHz, CD3CN): δ 161.0
(Ccarbene), 156.1, 150.4, 144.7, 125.9, 108.3 (Ar–C), 52.1, 46.7
(NCH2), 39.5 (NCH3), 23.3, 23.0, 22.5, 21.7, 21.1, 20.9 (CH2).
31P{1H} NMR (202.4 MHz, CD3CN): δ −143.1 (m, PF6). 19F{1H}
NMR (282.4 MHz, CD3CN): δ 3.46 (d, PF6). Anal. Calc. for
C18H26N4AuPF6: C, 33.76; H, 4.09; N, 8.75. Found: C, 33.85; H,
4.10; N, 8.51%. MS (ESI): m/z = 405 [M − PF6 − DMAP +
CH3OH]
+, 495 [M − PF6]+.
X-ray diﬀraction studies
X-ray data for 5·CHCl3, 6, and 9–11 were collected with a
Bruker AXS SMART APEX diﬀractometer, using Mo Kα radi-
ation at 100(2) K with the SMART suite of programs.14 Data
were processed and corrected for Lorentz and polarization
eﬀects with SAINT,15 and for absorption eﬀect with SADABS.16
Structural solution and refinement were carried out with the
SHELXTL suite of programs.17 The structures were solved by
direct methods to locate the heavy atoms, followed by diﬀer-
ence maps for the light, non-hydrogen atoms. All hydrogen
atoms were placed in calculated positions. All non-hydrogen
atoms were generally given anisotropic displacement para-
meters in the final model. A summary of the most important
crystallographic data is provided in Table 3.
Cytotoxicity studies
In vitro toxicities of 3–12 were determined by CellTiter 96
AQueous Non-Radioactive Cell Proliferation Assay (MTS).
NCI-H1666 cells were maintained in complete RPMI medium
with 10% FBS and 1% PenStrep. Standard DMSO solutions of
3–12 were diluted with complete RPMI medium, with the final
concentration of DMSO in each diluted solution being less
than 0.5%. The cells were seeded in 96-well plates at a density
of 2000 cells per well in 100 μL of complete RPMI medium
without antibiotics and cultured overnight at 37 °C in a
humidified atmosphere containing 5% CO2. A 100 μL portion
of media containing diﬀerent concentrations of 3–12 was
added in the wells to a final concentration from 0.0005 to
50 μM. Compound-free solvent controls were also included.
After a 72-hour incubation period, 20 μL of CellTiter 96
AQueous One Reagent containing the tetrazolium compound
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt) was added to each
well. After incubation for about 3 h, the absorbance was
measured at 490 nm using a Tecan Infinite M200 plate reader.
Nonlinear regression analysis was performed using GraphPad
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Prism version 5.00 for Windows to calculate the IC50 value of
each compound.
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